Jennison Associates

Jennison Associates

Jennison Associates

Active fundamental manager with single focus, strong investment culture and superior investment returns across capabilities for 45 years
Follow us
the home of AI info

Unum Therapeutics Inc. (UMRX)'s Financial Results Comparing With Minerva Neurosciences Inc ...

Xconomy

With “Inflection Year” Ahead, Ovid Adds Novartis’s Tardio to C-Suite

MedCity News

Editas Medicine CEO steps down as company moves into product development stage

$69,200,000 IPO
PE HUB

VC-backed Unum Therapeutics rolls out IPO

Stock markets Health
Xconomy

Unum Therapeutics IPO Raises $69M to Test Universal Cell Therapies

Health Stock markets
$75,000,000 IPO
Xconomy

With $75M Haul, Ovid Continues Flurry of Biotech IPOs

Health Science
$15,000,000 Debt financing
FinSMEs

Unum Therapeutics Receives $15M Credit Facility from Square 1 Bank

Xconomy

Merrimack Hits Reset Button, Sells Cancer Drugs to Ipsen For $575M

Health Strategy Earnings
Xconomy

Still Stuck Below IPO Price, Merrimack Restructures, CEO Resigns

Health Earnings
The Motley Fool

Here's Why Merrimack Pharmaceuticals' Stock Has Been Getting Crushed in 2016

The Motley Fool

Why Merrimack Pharmaceuticals' Stock Is Sliding Today

$94,000,000 IPO
GeekWire , WIRED

Editas Medicine raises $94M in first gene-editing IPO, and then stock price rises

Science Stock markets
Xconomy

As Markets and Controversies Swirl, Editas Aims For $100M CRISPR IPO

Science Health
The Motley Fool

Natera, Inc. Surged 20% Higher in December. Here's Why. --

Stock markets
GeekWire

Gates-backed Editas Medicine files for IPO, marking CRISPR gene-editing milestone

Science Funding
$75,000,000 Venture capital (Series B)
Xconomy

Ex-Teva CEO's Brain Disease Startup, Ovid, Bags $75M From Crossovers

Health Funding
Xconomy

Prenatal Tester Natera Now Shooting for $175M IPO

Health Funding